mRNA |
1 |
BNT162b2 |
Pfizer-BionTech |
A lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2 |
Fatigue, headache, muscle pain, chills, myocarditis and pericarditis |
31 December 2020 |
2 doses 21 days apart |
95–87.5% |
USA |
[99], [100]
|
2 |
mRNA-1273SPIKEVAX |
Moderna |
Based on mRNA and is a cutting- edge approach that uses genetically engineered RNA to generate a protein that itself safely prompts an immune response. |
Pain at the injection site, nausea, vomiting, fever, fatigue, myocarditis and pericarditis |
30 April 2021 |
2 doses 28 days apart |
94.1% |
USA |
[101] |
Viral vector |
3 |
ChAdOx1-S or AZD1222 or Vaxzevria |
Astra-Zeneca/Oxford |
Based on Adenovirus Viral vector vaccines use a virus that has been genetically engineered so that it cannot cause disease but produces coronavirus proteins to safely generate an immune response. |
Rare cases of blood clots and Guillain-Barré syndrome [GBS] |
15 February 2021 |
2 doses 4–12 weeks apart |
70% |
UK |
[99], [102]
|
4 |
Ad.26. COV2. S or JNJ- 78436725 |
Janssen (Johnson & Johnson) |
Is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector vaccine, encoding the stabilized prefusion spike glycoprotein of virus |
Rare case of blood clots, thrombocytopenia and Guillain-Barré syndrome [GBS] |
12 March 2021 |
1 dose |
72–57% |
USA |
[99], [103]
|
Inactivated |
5 |
BBIBP-CorV Sinopharm |
Beijing Institute of Biological Products Co., Ltd. (BIBP) |
Inactivated virus (HB02 strain) vaccine that introduces a dead copy of SARS-CoV-2 into the body |
Pain at the vaccination site, fatigue, lethargy, headache and tenderness |
7 May 2021 |
2 doses 14–12 days apart |
79% |
China |
[104] |
6 |
CoronaVac |
Sinovac |
Inactivated or weakened virus (CZ02 strain) vaccines are based on a form of the virus that has been inactivated or weakened so that it does not cause disease but is still able to generate an immune response. |
Injection site reactions, included fatigue, diarrhea, and muscle pain |
1 June 2021 |
2 doses 14 days apart |
65.9% |
China |
[105] |
7 |
COVAXIN |
Bharat Biotech |
Whole virion inactivated SARS-CoV-2 vaccine |
Pain at the injection site, followed by headache, fever, and fatigue |
3 November 2021 |
2 doses 4 weeks apart |
78% |
India |
[106], [107], [108]
|
Recombinant nanoparticle and virus-like particle |
8 |
COVOVAX |
Serum Institute of India Pvt. Ltd |
(SARS-CoV-2 rS Protein Nanoparticle [Recombinant]) |
|
17 December 2021 |
|
|
India |
[109] |
9 |
NVX-CoV2373 NUVAXOVID |
Novavax |
SARS-CoV-2 rS [Recombinant, adjuvanted]. Synthetic nanoparticle coated with trimer spike protein with matrix M adjuvant |
Injection-site tenderness, fever, headache, muscle pain, and fatigue |
20 December 2021 |
2 doses 21 days apart |
89.7% |
Czech Republic |
[110] |